Algoritmo sistemático de aprendizado de máquina para detecção de trombose rápida (DVT-SMART)
Avaliando uma nova estratégia de diagnóstico para suspeita de TVP, consistindo em Point of Care D-Dimer, modelo de previsão baseado em IA e ultrassom de compressão
The goal of this clinical trial is to compare the use of a machine learning-based algorithm and point-of-care D-dimer to laboratory D-dimer and compression ultrasound to exclude deep vein thrombosis in the under extremities in patients referred to a medical department suspected of having deep vein thrombosis. The main aim is to answer are if a machine learning algorithm and point of care D-dimer can exclude deep vein thrombosis in more patients than clinical assessment and D-dimer alone.
Visão geral do estudo
Status
Condições
Descrição detalhada
All participants will follow the usual diagnostic algorithm used for patients with suspected DVT referred to Ostfold Hospital (all patients are examined by a physician, D-dimer is analyzed in all patients, ultrasound is performed by a radiologist in patients with positive D-dimer). In addition to usual care, POC D-dimer, POC ultrasound (performed by ED physicians), blood sampling for biobanking, and photographies of the under extremities will be performed. The machine learning model will be tested to see if the prediction is correct. In participants where ultrasound is performed, it will also be assessed whether the machine learning algorithm could have excluded the participant without the use of ultrasound. None of the additional procedures will have any impact on the patient diagnostics or treatment.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Waleed Ghanima, Professor
- Número de telefone: 0047 69860000
- E-mail: waleed.ghanima@so-hf.no
Estude backup de contato
- Nome: Hans Joakim Myklebust-Hansen, Medical Doctor
- Número de telefone: 0047 97501765
- E-mail: hans.joakim.hansen@so-hf.no
Locais de estudo
-
-
-
Sarpsborg, Noruega, 1714
- Recrutamento
- Østfold Hospital Trust
-
Contato:
- Hans J Myklebust-Hansen, M.D.
- Número de telefone: 004797501765
- E-mail: hansjoakim_mh@outlook.com
-
Subinvestigador:
- Hans J Myklebust-Hansen, M.D.
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Patients referred to the ED due to suspicion of DVT
- Age ≥ 18 years
- Able to give informed consent
Exclusion Criteria:
- Ongoing use of anticoagulation for more than 72 hours
- Previous participation in the study
- Life expectancy of less than three months.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Diagnóstico
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: All participants
All participants will be treated the same way. |
POC D-dimer will be compared to laboratory D-dimer in hospital setting and used in a machine learning model Point of care (POC) ultrasound performed by ED physicians compared to ultrasound performed by radiologist. POC ultrasound 3 point examination performed by ED physician will be compared with POC ultrasound full leg examination performed by ED physician. The DSS will be compared to the usual strategy. It will also be estimated how many participants where DVT could have been excluded without ultrasound.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Safety of the new strategy (POC D-dimer, ML-based prediction model, POC CUS by emergency physician)
Prazo: From enrollment to the end of the primary assessment period (90 days)
|
Evaluate the safety of a new strategy consisting of POC D-dimer and an ML-based prediction model followed by CUS performed by emergency physicians by comparing the new strategy's safety with our standard care by measuring the proportion of patients in whom DVT is excluded according to the new strategy but was diagnosed with DVT by standard care or in whom DVT is diagnosed within the 90-day follow up. |
From enrollment to the end of the primary assessment period (90 days)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Evaluate the efficiency of the new strategy
Prazo: From enrollment to the end of the primary assessment period (90 days)
|
The proportion of patients in whom DVT can be ruled out by the ML-based prediction model with POC D-dimer compared to the efficiency of Wells score and laboratory D-dimer |
From enrollment to the end of the primary assessment period (90 days)
|
|
Validate the safety and efficiency of the ML-based prediction model
Prazo: From enrollment to the end of the primary assessment period (90 days)
|
Safety will be determined by the proportion of patients in whom DVT is excluded by the ML-model but diagnosed by standard care. Efficiency will be determined by the proportion of patients in whom DVT can be excluded by the ML-based model |
From enrollment to the end of the primary assessment period (90 days)
|
|
Evaluate concordance between CUS performed by emergency physicians and radiologists.
Prazo: From time of enrollment until time of ultrasound examination performed by radiologist, assessed up to 48 hours.
|
Determine the proportion of false negative and false positive diagnosis of DVT in emergency physician-performed ultrasound compared with ultrasound performed by radiologists. |
From time of enrollment until time of ultrasound examination performed by radiologist, assessed up to 48 hours.
|
|
Evaluate concordance between POC D-dimers in an ED setting and laboratory D-dimers.
Prazo: From enrollment to the completion of D-dimer analysis, assessed up to 24 hours.
|
Compare the two POC D-dimers with the STA-Liatest D-dimer and Siemens INNOVANCE by direct comparison of the true/false positive/negative results. |
From enrollment to the completion of D-dimer analysis, assessed up to 24 hours.
|
|
Evaluate the hypothetical time to be completed for the novel strategy compared to the standard strategy.
Prazo: From time of enrollment until time of discharge from the emergency department either discharged from the hospital or hospitalized, assessed up to 24 hours.
|
Estimating the total management time defined as time from ED registration to ED discharge in patients evaluated according to the new strategy compared to standard care. |
From time of enrollment until time of discharge from the emergency department either discharged from the hospital or hospitalized, assessed up to 24 hours.
|
|
Evaluate the safety of a limited ultrasound protocol (two-point and proximal) compared to full-leg CUS performed by emergency physicians and radiologists
Prazo: 90 days after enrollment.
|
Estimating the proportion of patients in whom DVT was ruled out by the limited ultrasound protocol but was diagnosed with DVT by the whole-leg ultrasound. |
90 days after enrollment.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 682139
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The plan to share IPD with other researchers are not yet decided because it has not yet been discussed.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .